Using the chronic constriction injury (CCI) model of neuropathic pain, we profiled gene expression in the rat spinal cord, and identified SIP30 as a gene whose expression was elevated after CCI. SIP30 was previously shown to interact with SNAP25, but whose function was otherwise unknown. We now show that in the spinal cord, SIP30 was present in the dorsal horn laminae where the peripheral nociceptive inputs first synapse, co-localizing with nociception-related neuropeptides CGRP and substance P. With the onset of neuropathic pain after CCI surgery, SIP30 mRNA and protein levels increased in the ipsilateral side of the spinal cord, suggesting a potential association between SIP30 and neuropathic pain. When CCIupregulated SIP30 was inhibited by intrathecal antisense oligonucleotide administration, neuropathic pain was attenuated. This neuropathic pain-reducing effect was observed both during neuropathic pain onset following CCI, and after neuropathic pain was fully established, implicating SIP30 involvement in the development and maintenance phases of neuropathic pain. Using a secretion assay in PC12 cells, anti-SIP30 siRNA decreased the total pool of synaptic vesicles available for exocytosis, pointing to a potential function for SIP30. These results suggest a role of SIP30 in the development and maintenance of peripheral nerve injury-induced neuropathic pain. Ó
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Using the chronic constriction injury (CCI) model of neuropathic pain, we profiled gene expression in the rat spinal cord, and identified SIP30 as a gene whose expression was elevated after CCI. SIP30 was previously shown to interact with SNAP25, but whose function was otherwise unknown. We now show that in the spinal cord, SIP30 was present in the dorsal horn laminae where the peripheral nociceptive inputs first synapse, co-localizing with nociception-related neuropeptides CGRP and substance P. With the onset of neuropathic pain after CCI surgery, SIP30 mRNA and protein levels increased in the ipsilateral side of the spinal cord, suggesting a potential association between SIP30 and neuropathic pain. When CCIupregulated SIP30 was inhibited by intrathecal antisense oligonucleotide administration, neuropathic pain was attenuated. This neuropathic pain-reducing effect was observed both during neuropathic pain onset following CCI, and after neuropathic pain was fully established, implicating SIP30 involvement in the development and maintenance phases of neuropathic pain. Using a secretion assay in PC12 cells, anti-SIP30 siRNA decreased the total pool of synaptic vesicles available for exocytosis, pointing to a potential function for SIP30. These results suggest a role of SIP30 in the development and maintenance of peripheral nerve injury-induced neuropathic pain.
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Introduction
Neuropathic pain is a chronic and persistent painful condition, originating from nerve damage or dysfunction. Different from somatic pain that tends to subside after the injury heals, neuropathic pain often continues long after the initial injury has healed, and may persist in the absence of observable tissue damage. Effective alleviation of neuropathic pain remains clinically challenging, since neuropathic pain is refractory to the available therapeutic means in many patients [1, 4, 5, 12] . Indeed, a recent survey of treatment options for neuropathic pain noted that ''existing pharmacologic treatments for neuropathic pain are limited, with no more than 40-60% of patients obtaining partial relief of their pain" [14] . To develop more effective therapeutic approaches, it is crucial to understand the mechanistic basis for neuropathic pain, and to identify molecules involved in the development and maintenance of neuropathic pain.
SIP30 is a SNAP25 (synaptosome-associated proteins of 25 kDa) interacting protein of 30 kDa [23] . This novel protein of 266 amino acids, like all SNAREs (soluble N-ethylmaleimide-sensitive factor attachment protein receptors), has a coiled-coil domain that forms a key component in protein-protein interactions [11, 23, 31] . SNAREs, including t-SNAREs (localized to the target membrane, grouped into the synaptosome-associated proteins of 25 kDa, and syntaxin families) and v-SNAREs (localized to the membrane of the trafficking vesicle, comprising vesicle-associated membrane proteins, VAMPs) are essential for regulated exocytosis of synaptic vesicles during neurotransmission [7, 8, 15, 32, 35] . SIP30 has been detected in various brain areas [23, 26] . However, molecular and cellular functions for SIP30 remain unknown so far. In this study, we present evidence for a functional role of SIP30 in the development and maintenance of neuropathic pain, using the chronic constriction injury (CCI) model. 
